ARTICLE | Company News
Neurogen, Aventis deal
December 24, 2001 8:00 AM UTC
AVE licensed exclusive worldwide rights to NRGN's corticotrophin releasing factor ( CRF1) antagonist compounds, including its lead, NGD 98-2, for use in treating depression, anxiety and other stress-r...